PERK Is Dispensable for Smooth Muscle Cell Phenotype Switching in Atherosclerosis
- 1 July 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (7)
Abstract
BACKGROUND: Smooth muscle cell (SMC)-derived cells form the bulk of cells in atherosclerotic lesions and modulate lesion stability and cardiovascular disease outcomes. Unfolded protein response (UPR) markers, thin fibrous caps, and inflammation correlate with human lesion instability and rupture. In mice, UPR drives macrophage and endothelial apoptosis and inflammation, but its impact on lesion stability through SMC modulation is debated. The UPR protein PERK (protein kinase RNA-like ER kinase) was recently shown to drive SMC modulation in vivo, suggesting that depletion of SMC Perk may regulate lesion stability. METHODS: SMC Perk was deleted from SMC-lineage-traced adult Ldlr −/− hypercholesterolemic mice. Lesions were scored for features of lesion stability and analyzed for differential expression at the single-cell level. Perk knockdown in primary murine SMCs was used to study Perk’s effect on SMC modulation in vitro. Human carotid lesions were assessed for UPR markers through scRNA-seq, bulk RNA-seq, and Xenium spatial transcriptomics. RESULTS: SMC Perk deletion in adult atherogenic mice did not affect weight gain or serum cholesterol levels. Lesions from Perk knockout mice resembled Perk WT counterparts with similar progression, lesion stability features, and cell populations. Scoring of UPR markers and differential expression analysis found little UPR activity in SMC and smooth muscle-derived cell populations. Perk was not required for in vitro SMC modulation in atherogenic conditions. No correlation was found between UPR markers and lesion stability or symptomatic clinical presentation in human carotid lesions, and UPR markers were expressed primarily in infiltrating leukocytes rather than in SMCs and stromal cells. CONCLUSIONS: SMC Perk UPR does not play a significant role in atherosclerotic SMC modulation, disease progression, or features of lesion stability in mice. Similarly, expression of markers of the Perk UPR pathway in humans does not correlate with human carotid lesion stability or clinical presentation.Keywords
This publication has 56 references indexed in Scilit:
- Trimethylamine N-oxide promotes PERK-mediated endothelial-mesenchymal transition and apoptosis thereby aggravates atherosclerosisInternational Immunopharmacology, 2024
- The Greatly Under-Represented Role of Smooth Muscle Cells in AtherosclerosisCurrent Atherosclerosis Reports, 2023
- Downregulation of activating transcription factor 4 attenuates lysophosphatidycholine-induced inflammation via the NF-κB pathwayEuropean Journal of Pharmacology, 2021
- Enhanced cellular cholesterol efflux by naringenin is mediated through inhibiting endoplasmic reticulum stress - ATF6 activity in macrophagesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2019
- KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesisNature Medicine, 2015
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular EventsJACC, 2014
- Progress and challenges in translating the biology of atherosclerosisNature, 2011
- Reduced Apoptosis and Plaque Necrosis in Advanced Atherosclerotic Lesions of Apoe−/− and Ldlr−/− Mice Lacking CHOPCell Metabolism, 2009
- PERK is essential for neonatal skeletal development to regulate osteoblast proliferation and differentiationJournal of Cellular Physiology, 2008
- Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasiaCardiovascular Pathology, 2007